Objective: To investigate the effect of sacubitril-valsartan combined with Zhenyuan capsule in the treatment of chronic heart failure comorbid anxiety and depression and its effect on the level of inflammatory factors...Objective: To investigate the effect of sacubitril-valsartan combined with Zhenyuan capsule in the treatment of chronic heart failure comorbid anxiety and depression and its effect on the level of inflammatory factors. Methods: A total of 106 patients with chronic heart failure comorbid anxiety and depression from February 2020 to March 2022 were continuously enrolled and divided into control group (36 cases), observation group A (36 cases) and observation group B (34 cases) according to treatment methods. All groups were given conventional treatment. On the basis of routine treatment, the control group, observation group A and observation group B were given valsartan, sacubitril-valsartan and sacubitril-valsartan plus Zhenyuan Capsules for the treatment of consecutive 8 weeks. The patients in the 3 groups were evaluated by the Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) before and after treatment, and the clinical efficacy of heart failure was evaluated, and the detection of left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), N terminal brain natriuretic peptide (NT-proBNP), tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL-6), c-reactive protein (CRP) was conducted. Results: The clinical efficacy rate and total effective rate of heart failure in observation group A and observation group B were significantly higher than those in the control group (P < 0.05), and the observation group B was higher than the observation group A (P < 0.05);SAS and SDS scores in observation group A and observation group B were significantly lower than the control group (P < 0.05), and observation group B was lower than observation group A (P < 0.05);The LVEF in the three groups was all increased compared with those before treatment, and the levels of LVESD, LVEDD, NT-proBNP, TNF-α, IL-6, and hs-CRP were all decreased compared with those before treatment;The changes of above indexes in observation group A and observation group B were more significant than those in control group (P < 0.05). Except for the LVEDD index, the observation group B had significant changes compared with the observation group A (P < 0.05). Conclusion: Sacubitril valsartan can improve cardiac function, reduce inflammatory response, and improve anxiety and depression in patients with chronic heart failure, and the treatment effect of combination with Zhenyuan Capsule is more significant.展开更多
Objective: To investigate the effect of Dan seven soft capsule on the treatment of acute hemorrhagic cerebrovascular disease and the influence of serum inflammatory factors, coagulation function and blood rheology ind...Objective: To investigate the effect of Dan seven soft capsule on the treatment of acute hemorrhagic cerebrovascular disease and the influence of serum inflammatory factors, coagulation function and blood rheology indexes. Methods: A total of 112 cases of patients with acute hemorrhagic cerebrovascular disease, according to the random data table were divided into the control group (n=57) and observation group (n=55), the patients in the control group received routine treatment combined with edaravone, on the basis of the treatment of the control group, the observation group was treated with Dan seven soft capsule. The serum levels of inflammatory factors, coagulation function and blood rheology indexes were compared between the two groups before and after treatment. Results: Before treatment, there were no significant difference in the inflammatory factors (hs-CRP, TNF-α and IL-6), blood coagulation function (FIB, PT and APTT) and hemorheology (high cut whole blood viscosity, low cut whole blood viscosity and plasma viscosity) levels between the control group and observation group. Compared with the levels of the same group before treatment, two groups of hs-CRP, TNF-α, IL-6, FIB, high cut whole blood viscosity, low cut whole blood viscosity and plasma viscosity level after treatment were significantly decreased, and levels in the observation group were significantly lower than those in the control group;Compared with the group before treatment, the levels of PT and APTT in the two groups were significantly increased, and the observation group was significantly higher than the control group. Conclusion: Dan seven soft capsule in the treatment of acute hemorrhagic cerebrovascular disease can effectively reduce the level of serum inflammatory factors, improve coagulation function and blood rheology index, it has an important clinical value.展开更多
目的:研究加味藿香正气软胶囊(Jiawei Huoxiang Zhengqi soft capsule,JWHXZQ)对三硝基苯磺酸(2,4,6-trinitrobenzene sulfonic acid TNBS)诱导小鼠结肠炎模型的抗炎作用及其机制.方法:将50只B a l b/c♀小鼠随机分为对照组、模型组、J ...目的:研究加味藿香正气软胶囊(Jiawei Huoxiang Zhengqi soft capsule,JWHXZQ)对三硝基苯磺酸(2,4,6-trinitrobenzene sulfonic acid TNBS)诱导小鼠结肠炎模型的抗炎作用及其机制.方法:将50只B a l b/c♀小鼠随机分为对照组、模型组、J W H X Z Q低、中、高剂量(0.234、0.468、0.936 g/kg)组.采用TNBS/乙醇灌肠制作小鼠结肠炎模型,同时开始每天ig给药,连续7 d.每天进行疾病活动指数(disease activity index,DAI)评分,7 d后处死小鼠,对各组小鼠结肠进行组织病理学评分检测血清中NO水平、结肠组织中髓过氧化物酶(myeloperoxidase,MPO)含量及白介素(interleukin,IL)-1β、IL-6、IL-12、肿瘤坏死因子(tumor necrosis factor,TNF)-α、干扰素(interferon,IFN)-γ等促炎性细胞因子水平.结果:与模型组比较,JWHXZQ中、高剂量组治疗可显著降低TNBS结肠炎小鼠的DAI评分和病理学评分,降低小鼠血清中NO水平,同时还显著降低结肠中MPO含量、IL-1β、IL-6、IL-12和TNF-α等促细胞因子水平;JWHXZQ低剂量组也能显著降低小鼠血清中NO含量、结肠中IL-1β和IL-6水平.结论:JWHXZQ对TNBS诱导的小鼠结肠炎具有一定治疗作用,其机制可能与抑制促炎性细胞因子产生及相关免疫应答通路而发挥作用.展开更多
文摘Objective: To investigate the effect of sacubitril-valsartan combined with Zhenyuan capsule in the treatment of chronic heart failure comorbid anxiety and depression and its effect on the level of inflammatory factors. Methods: A total of 106 patients with chronic heart failure comorbid anxiety and depression from February 2020 to March 2022 were continuously enrolled and divided into control group (36 cases), observation group A (36 cases) and observation group B (34 cases) according to treatment methods. All groups were given conventional treatment. On the basis of routine treatment, the control group, observation group A and observation group B were given valsartan, sacubitril-valsartan and sacubitril-valsartan plus Zhenyuan Capsules for the treatment of consecutive 8 weeks. The patients in the 3 groups were evaluated by the Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) before and after treatment, and the clinical efficacy of heart failure was evaluated, and the detection of left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), N terminal brain natriuretic peptide (NT-proBNP), tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL-6), c-reactive protein (CRP) was conducted. Results: The clinical efficacy rate and total effective rate of heart failure in observation group A and observation group B were significantly higher than those in the control group (P < 0.05), and the observation group B was higher than the observation group A (P < 0.05);SAS and SDS scores in observation group A and observation group B were significantly lower than the control group (P < 0.05), and observation group B was lower than observation group A (P < 0.05);The LVEF in the three groups was all increased compared with those before treatment, and the levels of LVESD, LVEDD, NT-proBNP, TNF-α, IL-6, and hs-CRP were all decreased compared with those before treatment;The changes of above indexes in observation group A and observation group B were more significant than those in control group (P < 0.05). Except for the LVEDD index, the observation group B had significant changes compared with the observation group A (P < 0.05). Conclusion: Sacubitril valsartan can improve cardiac function, reduce inflammatory response, and improve anxiety and depression in patients with chronic heart failure, and the treatment effect of combination with Zhenyuan Capsule is more significant.
文摘Objective: To investigate the effect of Dan seven soft capsule on the treatment of acute hemorrhagic cerebrovascular disease and the influence of serum inflammatory factors, coagulation function and blood rheology indexes. Methods: A total of 112 cases of patients with acute hemorrhagic cerebrovascular disease, according to the random data table were divided into the control group (n=57) and observation group (n=55), the patients in the control group received routine treatment combined with edaravone, on the basis of the treatment of the control group, the observation group was treated with Dan seven soft capsule. The serum levels of inflammatory factors, coagulation function and blood rheology indexes were compared between the two groups before and after treatment. Results: Before treatment, there were no significant difference in the inflammatory factors (hs-CRP, TNF-α and IL-6), blood coagulation function (FIB, PT and APTT) and hemorheology (high cut whole blood viscosity, low cut whole blood viscosity and plasma viscosity) levels between the control group and observation group. Compared with the levels of the same group before treatment, two groups of hs-CRP, TNF-α, IL-6, FIB, high cut whole blood viscosity, low cut whole blood viscosity and plasma viscosity level after treatment were significantly decreased, and levels in the observation group were significantly lower than those in the control group;Compared with the group before treatment, the levels of PT and APTT in the two groups were significantly increased, and the observation group was significantly higher than the control group. Conclusion: Dan seven soft capsule in the treatment of acute hemorrhagic cerebrovascular disease can effectively reduce the level of serum inflammatory factors, improve coagulation function and blood rheology index, it has an important clinical value.
文摘目的:研究加味藿香正气软胶囊(Jiawei Huoxiang Zhengqi soft capsule,JWHXZQ)对三硝基苯磺酸(2,4,6-trinitrobenzene sulfonic acid TNBS)诱导小鼠结肠炎模型的抗炎作用及其机制.方法:将50只B a l b/c♀小鼠随机分为对照组、模型组、J W H X Z Q低、中、高剂量(0.234、0.468、0.936 g/kg)组.采用TNBS/乙醇灌肠制作小鼠结肠炎模型,同时开始每天ig给药,连续7 d.每天进行疾病活动指数(disease activity index,DAI)评分,7 d后处死小鼠,对各组小鼠结肠进行组织病理学评分检测血清中NO水平、结肠组织中髓过氧化物酶(myeloperoxidase,MPO)含量及白介素(interleukin,IL)-1β、IL-6、IL-12、肿瘤坏死因子(tumor necrosis factor,TNF)-α、干扰素(interferon,IFN)-γ等促炎性细胞因子水平.结果:与模型组比较,JWHXZQ中、高剂量组治疗可显著降低TNBS结肠炎小鼠的DAI评分和病理学评分,降低小鼠血清中NO水平,同时还显著降低结肠中MPO含量、IL-1β、IL-6、IL-12和TNF-α等促细胞因子水平;JWHXZQ低剂量组也能显著降低小鼠血清中NO含量、结肠中IL-1β和IL-6水平.结论:JWHXZQ对TNBS诱导的小鼠结肠炎具有一定治疗作用,其机制可能与抑制促炎性细胞因子产生及相关免疫应答通路而发挥作用.